Search results
Results from the WOW.Com Content Network
The following findings are required for substances to be placed in this schedule: The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II. The drug or other substance has a currently [1] accepted medical use in treatment in the United States.
[1] [2] These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.
It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), [1] as well as to aid in recovery after stroke.. A systematic review published in 1994 found little evidence to support the use of ergoloid mesylates, concluding only that potentially effective doses may be higher than those currently approved in dementia treatment.
The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness. [6] At high drug dosages, bradycardia, increased appetite, agitation, diarrhea and perspiration were reported. Most of the available literature suggests that the side effects of nicergoline are mild and transient. [2]
Some drugs used to treat type 2 diabetes could also help lower a person’s risk of neurodegenerative diseases, such as Alzheimer’s. Image credit: martin-dm/Getty Images.
The results of a new large-scale study published in The BMJ suggest that a relatively new diabetes drug might reduce the risk of developing dementia in people with type 2 diabetes.
Piracetam is in the racetams group, with chemical name 2-oxo-1-pyrrolidine acetamide. It is a cyclic derivative of the neurotransmitter GABA [4] and shares the same 2-oxo-pyrrolidone base structure with pyroglutamic acid. Related drugs include the anticonvulsants levetiracetam and brivaracetam, and the putative nootropics aniracetam and ...
A recent study found that a class of medications called SGLT-2 inhibitors—which does not include Ozempic or similar drugs like Zepbound—significantly lowered the risk of dementia in people ...